2020 Aug 1, 12:02am
125 views 3 comments
We wrote about AAPS back in April after the group published a report of its study that showed hydroxychloroquine to have about 90 percent chance of helping COVID-19 patients. At the time, the group reported that a total number of 2,333 coronavirus patients were treated with HCQ, with or without zinc and the widely used antibiotic azithromycin. The report was based on observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.In late June, the group filed its motion for a preliminary injunction with court to compel release to the public of hydroxychloroquine by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. HHS, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).As part of the filing with the court, AAPS also includes a chart showing how countries that encourage HCQ use, such as South Korea, India, Turkey, Russia, and Israel, have been far more successful in combatting COVID-19 than countries that have banned or discouraged early HCQ use, as the FDA has.